A 3-Year Experience with Tildrakizumab Treatment for Patients with Plaque Psoriasis in Clinical Practice.

Martina Burlando Ilaria SalviAurora ParodiEmanuele Cozzani

Published in: Dermatology and therapy (2024)

This long-term observation in the real life of patients with moderate-to-severe plaque psoriasis receiving tildrakizumab 100 mg showed that PASI100 can be obtained in a high proportion of patients by week 36 and be maintained for up to 3 years.

Keyphrases

clinical practice
end stage renal disease
coronary artery disease
newly diagnosed
chronic kidney disease
clinical trial
early onset
atopic dermatitis
study protocol
patient reported